Our data showing a central role for JAK1/STAT3/IL6 also suggest that it may be relevant to use anti-IL6 and JAK-inhibitors as early as possible in the course of RA, maybe at a stage when it may still be possible to prevent the acquisition of further epigenetic changes. The gene discussed is JAK1; the disease is rheumatoid arthritis.